Analytical Data
-
基因名
CDK2AP2
-
简介
The CDK2AP2 protein is an important component of the NuRD complex and actively participates in chromatin remodeling. It inhibits the G1/S phase transition by inhibiting CDK2 and preventing the interaction of CDK2 with cyclin E or A. CDK2AP2 Protein, Human (HEK293, His) is the recombinant human-derived CDK2AP2 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
别名
rHuCyclin-dependent kinase 2-associated protein 2/CDK2AP2, His; Cyclin-dependent kinase 2-associated protein 2; CDK2-associated protein 2; DOC-1-related protein; DOC-1R; CDK2AP2; DOC1R
-
种属
Human
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75956
-
表达区间
M1-T126
-
蛋白长度
Full Length
-
分子量
26 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK2AP2 (Cyclin-Dependent Kinase 2-Associated Protein 2) is a regulatory protein that has garnered attention due to its role in cell cycle regulation and potential implications in cancer biology. This protein functions as an inhibitor of cyclin-dependent kinases, specifically CDK2, which is crucial for the transition from the G1 phase to the S phase of the cell cycle. Dysregulation of CDK2 activity has been associated with various types of cancers, making CDK2AP2 a candidate for further investigation in tumor biology. Recent studies have suggested that CDK2AP2 may exhibit tumor-suppressive properties, potentially through its ability to modulate cell proliferation and promote apoptosis in cancer cells. Furthermore, the expression levels of CDK2AP2 may serve as a biomarker for prognostic evaluations in some malignancies. The recombinant expression of CDK2AP2 in vitro enables researchers to explore its biochemical properties, interactions with other cell cycle regulatory proteins, and its overall impact on cellular function. Understanding the mechanisms through which CDK2AP2 exerts its effects may provide valuable insights into therapeutic targets for the treatment of cancer and other proliferative disorders. As research in this area continues to evolve, CDK2AP2 represents a promising avenue for the development of novel cancer therapies aimed at restoring normal cell cycle regulation.
